Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP085: Ileocolonic involvement and diagnosis is related to fragments of the extracellular matrix measured in serum of patients with Crohn’s diseaseECCO '16 Amsterdam
Year: 2016
Authors:

J. H. Mortensen*1, M. D. Jensen2, J. Kjeldsen2, A. Krag2, M. Karsdal1, A.-C. Bay-Jensen1

1Nordic Bioscience, Biomarkers & Research, Herlev, Denmark, 2Odense University Hospital, Department of Gastroenterology, Odense, Denmark

DOP086: Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseasesECCO '16 Amsterdam
Year: 2016
Authors:

A. Buisson*1, 2, E. Vazeille1, 2, R. Minet Quinard3, M. Goutte1, 2, D. Bouvier3, F. Goutorbe1, B. Pereira4, N. Barnich2, G. Bommelaer1, 2

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, 2UMR 1071 Inserm/Université d’Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France, 3University Hospital G. Montpied, Biochemistry laboratory, Clermont-Ferrand, France, 4GM – Clermont-Ferrand University and Medical Centre, Biostatistics Unit, Clermont-Ferrand, France

DOP087: MMP degraded type III collagen is a novel serological biomarker for penetrating (Montreal B3) Crohn’s diseaseECCO '16 Amsterdam
Year: 2016
Authors:

W. T. van Haaften*1, 2, J. H. Mortensen3, M. A. Karsdal3, A.-C. Bay-Jensen3, G. Dijkstra2, P. Olinga1

1University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen, Netherlands, 2University Medical Centre Groningen, Department of Gastro-enterology and Hepatology, Groningen, Netherlands, 3Nordic Bioscience, Biomarkers and Research, Herlev, Denmark

DOP088: Inflammatory biomarkers in serum discriminate Crohn’s disease and ulcerative colitis from healthy controlsECCO '16 Amsterdam
Year: 2016
Authors:

E. Andersson*1, D. Bergemalm1, R. Kruse1, M. D’Amato2, D. Repsilber1, J. Halfvarson1

1Örebro University, Faculty of Medicine and Health, Örebro, Sweden, 2Karolinska Institutet, Department of Medicine, Solna, Sweden

DOP089: Microbiota profiles in treatment-naïve Norwegian IBD and non-IBD patients: part of the European Union IBD character consortiumECCO '16 Amsterdam
Year: 2016
Authors:

P. Ricanek*1, S. Vatn1, T. Lindahl2, E. Ciemniejewska2, J. Jahnsen1, C. Casen2, M. H. Vatn1

1Akershus University Hospital, Department of Gastroenterology, Lørenskog/Nordbyhagen, Norway, 2Genetic Analysis AS, Oslo, Norway

DOP090: The role of the microbiome in clinical response to golimumab in ulcerative colitisECCO '16 Amsterdam
Year: 2016
Authors:

C. Monast*, S. Telesco, K. Li, K. Hayden, C. Brodmerkel

Janssen R & D, LLC, Spring House, Pennsylvania, United States

OP001: A phase III randomised controlled trial of Cx601, expanded allogeneic adipose-derived mesenchymal stem cells (eASC), for complex perianal fistulas in Crohns diseaseECCO '16 Amsterdam
Year: 2016
Authors:

J. Panés*1, D. García-Olmo2, G. Van Assche3, J. F. Colombel4, W. Reinisch5, D. C. Baumgart6, M. Nachury7, M. Ferrante3, L. Kazemi-Shirazi5, J. C. Grimaud8, F. de la Portilla9, E. Goldin10, A. Leselbaum11, M. C. Diez11, S. Danese12

1Hospital Clinic Barcelona, Barcelona, Spain, 2Hospital U. Fundación Jiménez-Díaz, Madrid, Spain, 3University Hospitals Leuven, KU Leuven, Leuven, Belgium, 4Icahn School of Medicine at Mount Sinai, New York, New York, United States, 5Medical University of Vienna, Vienna, Austria, 6Charité Medical School - Humboldt-University of Berlin, Berlin, Germany, 7CHU Lille, Lille, France, 8Hôpital Nord, Marseille, France, 9Hospital Virgen del Rocío, Sevilla, Spain, 10Sharee Zedek MC, Jerusalem, Israel, 11TiGenix, Madrid, Spain, 12Istituto Clinico Humanitas, Milano, Italy

OP002: Histopathological response and remission after dual topical application of the Toll-like receptor 9 agonist DIMS0150 in patients with moderate-to-severe ulcerative colitisECCO '16 Amsterdam
Year: 2016
Authors:

R. Atreya*1, A. Öst2, C. Admyre3, A. Karlsson3, T. Knittel3, J. Kowalski3, F. Scaldaferi4, M. Neurath1, C. Hawkey5

1University of Erlangen-Nuernberg, Department of Medicine 1, Erlangen, Germany, 2Aleris Medilab, Department of Pathology and Cytology, Täby, Sweden, 3Index Pharmaceuticals, Stockholm, Sweden, 4Catholic University of Rome, Internal Medicine Department / Gastroenterology Division, Rome, Italy, 5Nottingham University Hospitals, Department of Gastroenterology, Nottingham, United Kingdom

OP003: Predicting short and medium-term efficacy of the biosimilar infliximab: trough levels/do anti-drug antibodys or clinical/biochemical markers play a more important role?ECCO '16 Amsterdam
Year: 2016
Authors:

P. A. Golovics*1, Z. Vegh1, M. Rutka2, K. Gecse1, A. Balint2, K. Farkas2, J. Banai3, L. Bene4, B. Gasztonyi5, T. Kristof6, L. Lakatos7, P. Miheller8, K. Palatka9, A. Patai10, A. Salamon11, T. Szamosi3, Z. Szepes12, G.T. Toth13, A. Vincze14, E. Biro15, B. Lovasz1, Z. Kurti1, F. Nagy12, T. Molnar2, P. Lakatos1

1Semmelweis University, First Department of Medicine, Budapest, Hungary, 2University of Szeged, First Department of Medicine, Szeged, Hungary, 3Military Hospital, State Health Centre, Department of Gastroenterology, Budapest, Hungary, 4Peterfy Hospital, First Department of Medicine, Budapest, Hungary, 5Zala County Hospital, Second Department of Medicine, Zalaegerszeg, Hungary, 6B-A-Z County and University Teaching Hospital, Second Department of Medicine, Miskolc, Hungary, 7Csolnoky F. Province Hospital, Department of Medicine, Veszprem, Hungary, 8Semmelweis University, Second Department of Medicine, Budapest, Hungary, 9University of Debrecen, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary, 10Markusovszky Hospital, First Department of Medicine and Gastroenterology, Szombathely, Iceland, 11Tolna County Teaching Hospital, First Department of Gastroenterology, Szekszard, Hungary, 12University of Szeged, First Department of Internal Medicine, Szeged, Hungary, 13Janos Hospital, Department of Gastroenterology, Budapest, Hungary, 14University of Pécs, First Department of Medicine, Pécs, Hungary, 15Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary

OP004: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric Crohns diseaseECCO '16 Amsterdam
Year: 2016
Authors:

A. Stojmirovic*, R. Dobrin, R. Strauss, D. Chan, K. Li, J. Friedman

Janssen R & D, LLC, Spring House, Pennsylvania, United States

OP005: A variable number of tandem repeat polymorphism in the promotor region of the neonatal Fc receptor affects anti-tumour necrosis factor serum levels in inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

T. Billiet*1, I. Cleynen1, M. Ferrante2, G. Van Assche2, A. Gils3, S. Vermeire2

1Department of Clinical and Experimental Medicine, KU Leuven, Translational Research in Gastrointestinal Disorders (TARGID), Leuven, Belgium, 2University Hospitals Leuven, Gastroenterology - 
Translational Research Centre for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Leuven, Belgium

OP006: Autophagy regulates dendritic cell migration through Rac1: implications for thiopurine therapyECCO '16 Amsterdam
Year: 2016
Authors:

M. Wildenberg*1, P. Koelink2, K. Diederen2, A. te Velde2, V. Nuij3, M. Peppelenbosch3, M. Nobis4, O. Sansom4, C.J. van der Woude3, G. D’Haens1, G. van den Brink1

1Academic Medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands, 2Academic Medical Centre, Tytgat Institute, Amsterdam, Netherlands, 3Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, 4Beatson Institute for Cancer Research, Glasgow, United Kingdom

OP007: Comprehensive epigenome-wide DNA methylation profiling in inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

N. Ventham*1, N. Kennedy1, A. Adams1, R. Kalla1, S. Heath2, K. O’Leary1, H. Drummond1, D. Wilson3, T. IBD-BIOM Consortium1, T. IBD-CHARACTER Consortium1, I. Gut2, E. R. Nimmo1, J. Satsangi1

1University of Edinburgh, CGEM, Edinburgh, United Kingdom, 2Centro Nacional de Análisis Genómico, Barcelona, Spain, 3University Of Edinburgh, Department of Child Life and Health, Edinburgh, United Kingdom

OP008: Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitisECCO '16 Amsterdam
Year: 2016
Authors:

R. Alberts*1, E. M. de Vries2, G. Alexander3, D. Alvaro4, A. Bergquist5, U. Beuers2, E. Björnsson6, K. M. Boberg7, C. L. Bowlus8, R. W. Chapman9, O. Chazouillères10, A. Cheung11, G. Dalekos12, B. Eksteen13, D. Ellinghaus14, M. Färkkilä15, E. A. Festen1, A. Floreani16, T. Folseraas7, E. Goode17, D. N. Gotthardt18, G. M. Hirschfield19, B. van Hoek20, K. Holm7, S. Hohenester21, J. R. Hov7, F. Imhann1, P. Invernizzi22, X. Jiang7, J. Eaton23, B. D. Juran24, K. N. Lazaridis24, V. Leppa25, J. Z. Liu26, J. Löfberg27, M. P. Manns28, H.-U. Marschall29, M. Marzioni30, A. L. Mason31, E. Melum7, P. Milkiewicz32, T. Müller33, A. Pares34, C. Rupp35, S. M. Rushbrook36, C. Rust37, F. Sampaziotis38, R. N. Sandford39, C. Schramm40, S. Schreiber14, E. Schrumpf7, M. Silverberg41, B. Srivastava39, M. Sterneck42, A. Teufel43, L. Tittmann44, L. Vallier38, A. V. Vila1, B. de Vries1, T. J. Weismüller28, C. Wijmenga45, K. Zachou46, A. Franke14, C. A. Anderson47, T. H. Karlsen7, C. Y. Ponsioen2, R. K. Weersma1

1University of Groningen and University Medical Centre Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, 2Academic Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, 3University of Cambridge, Department of Medicine, Division of Hepatology, Cambridge, United Kingdom, 4Sapienza University of Rome, Department of Clinical Medicine, Division of Gastroenterology, Rome, Italy, 5Karolinska University Hospital Huddinge, Karolinska Institutet, Department of Gastroenterology and Hepatology, Stockholm, Sweden, 6Landspitali University Hospital, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Reykjavik, Iceland, 7Oslo University Hospital, Rikshospitalet, Norwegian PSC Research Centre, Division of Cancer Medicine, Surgery and Transplantation, Oslo, Norway, 8University of California Davis, Division of Gastroenterology and Hepatology, Davis, California, United States, 9John Radcliffe University Hospitals NHS Trust, Department of Hepatology, Oxford, United Kingdom, 10Hôpital Saint Antoine and U.P.M.C. Univ Paris 06, AP-HP and Department of Hepatology, Paris, France, 11University Health Network - Toronto General Hospital, Gen. Internal Medicine, Toronto, Canada, 12Medical School, University of Thessaly, Department of Medicine and Research Laboratory of Internal Medicine, Larissa, Greece, 13University of Calgary, Snyder Institute of Chronic Diseases, Department of Medicine, Calgary, Canada, 14Christian-Albrechts-University of Kiel, Institute of Clinical Molecular Biology, Kiel, Germany, 15Helsinki University Hospital, Division of Gastroenterology, Department of Medicine, Helsinki, Finland, 16University of Padova, Dept. of Surgical, Oncological and Gastroenterological Sciences, Padova, Italy, 17Norfolk and Norwich University Hospital, Department of Gastroenterology, Norwich, United Kingdom, 18University Hospital of Heidelberg, Department of Medicine, Heidelberg, Germany, 19University of Toronto, Division of Gastroenterology, Department of Medicine, Toronto, Canada, 20Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, 21University of Munich, Department of Medicine II, Munich, Germany, 22Humanitas Clinical and Research Centre, Centre for Autoimmune Liver Diseases, Rozzano, Italy, 23Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, Minnesota, United States, 24Mayo Clinic, College of Medicine, Centre for Basic Research in Digestive Diseases, Division of Gastroenterology and Hepatology, Rochester, Minnesota, United States, 25Institute for Molecular Medicine Finland F.I.M.M., University of Helsinki and National Institute for Health and Welfare, Public Health Genomics Unit, Helsinki, Finland, 26Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom, 27Karolinska Institute, Department of, Stockholm, Sweden, 28Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany, 29Institute of Medicine, Sahlgrenska Academy and University Hospital, Department of Internal Medicine, Gothenburg, Sweden, 30Università Politecnica delle Marche, Ospedali Riuniti University Hospital, Department of Gastroenterology, Ancona, Italy, 31University of Alberta, Division of Gastroenterology and Hepatology, Edmonton, Alberta, Canada, 32Medical University of Warsaw, Liver and Internal Medicine Unit, Warsaw, Poland, 33Charité Universitätsmedizin Berlin, Department of Internal Medicine, Hepatology and Gastroenterology, Berlin, Germany, 34University of Barcelona, Liver Unit, Hospital Clinic, I.D.I.B.A.P.S., C.I.B.E.R.ehd, Barcelona, Spain, 35University Hospital of Heidelberg, Department of Internal Medicine IV, Heidelberg, Germany, 36University Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Norfolk and Norwich, Norwich, United Kingdom, 37University of Munich, Department of Medicine 2, Grosshadern, Munich, Germany, 38Wellcome Trust-Medical Research Council Stem Cell Institute, Anne McLaren Laboratory, Cambridge, United Kingdom, 39University of Cambridge, Academic Department of Medical Genetics, Cambridge, United Kingdom, 40University Medical Centre Hamburg-Eppendorf, 1st Department of Medicine, Hamburg, Germany, 41Mount Sinai Hospital Toronto, Inflammatory Bowel Disease Group, Zane Cohen Centre for Digestive Diseases, Toronto, Ontario, Canada, 42University Medical Centre Hamburg-Eppendorf, Department of Hepatobiliary Surgery and Transplantation, Hamburg, Germany, 43University of Mainz, First Department of Medicine, Mainz, Germany, 44Christian-Albrechts-University of Kiel, Institute for Epidemiology, Kiel, Germany, 45University of Groningen and University Medical Centre Groningen, Department of Genetics, Groningen, Netherlands, 46University of Thessaly, Department of Internal Medicine, Larissa, Greece, 47Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, Massachusetts, United States

OP009: Gene-microbiome interactions underlying the onset and the clinical phenotypes of inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

F. Imhann*1, A. Vich Vila1, M. J. Bonder2, D. Gevers3, J. Fu2, M. C. Visschedijk1, L.M. Spekhorst1, L. Franke2, H. van Dullemen1, R. W. F. Ter Steege1, C. Huttenhower4, G. Dijkstra1, R. J. Xavier3, C. Wijmenga2, E. A. M. Festen1, A. Zhernakova2, R. K. Weersma1

1University of Groningen and University Medical Centre Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, 2University of Groningen and University Medical Centre Groningen, Department of Genetics, Groningen, Netherlands, 3The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, 4Harvard School of Public Health, Biostatistics Department, Boston, Massachusetts, United States

OP010: Azathioprine dose reduction in patients with inflammatory bowel disease on combination therapy: a prospective studyECCO '16 Amsterdam
Year: 2016
Authors:

E. Del Tedesco1, S. Paul2, H. Marotte3, C. Jarlot1, N. Williet4, J. M. Phelip4, L. Peyrin Biroulet5, J. F. Colombel6, X. Roblin*4

1University Hospital, Gastroenterology, Saint-Etienne, France, 2University of Saint-Etienne, Immunology, Saint-Etienne, France, 3University Hospital, Rheumatology, Saint-Etienne, France, 4CHU Saint-Etienne, Saint-Etienne, France, 5CHU de Nancy, Department of Gastroenterology, Vandoeuvre-lès-nancy, France, 6Mount Sinai Hospital, New York, New York, United States

OP011: Comparison of adalimumab monotherapy and a combination with azathioprine for patients with Crohns disease: a prospective, multicentre, open-labelled clinical trial (DIAMOND study)ECCO '16 Amsterdam
Year: 2016
Authors:

T. Matsumoto*1, S. Motoya2, K. Watanabe3, T. Hisamatsu4, H. Nakase5, N. Yoshimura6, T. Ishida7, S. Kato8, T. Nakagawa9, M. Esaki10, M. Nagahori11, T. Matsui12, Y. Naito13, T. Kanai14, Y. Suzuki15, M. Nojima16, M. Watanabe11, T. Hibi17

1Iwate Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan, 2Sapporo Kosei General Hospital, Inflammatory Bowel Disease Centre, Sapporo, Japan, 3Osaka City General Hospital, Division of Gastroenterology, Osaka, Japan, 4Kyorin University School of Medicine, The Third Department of Internal Medicine, Tokyo, Japan, 5Kyoto University, Department of Gastroenterology and Hepatology, Endoscopic Medicine, Kyoto, Japan, 6Tokyo Yamate Medical Centre, Department of Medicine, Division of Gastroenterology, Tokyo, Japan, 7Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan, 8Saitama Medical Centre, Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe, Japan, 9Chiba University, Department of Gastroenterology and Nephrology (K1), Graduate School of Medicine, Chiba, Japan, 10Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan, 11Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, 12Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, 13Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Department of Molecular Gastroenterology and Hepatology, Kyoto, Japan, 14Keio University, Department of Internal Medicine, School of Medicine, Tokyo, Japan, 15Toho University Sakura Medical Centre, Department of Internal Medicine, Sakura, Japan, 16The Institute of Medical Science Hospital, The University of Tokyo, Centre for Translational Research, Tokyo, Japan, 17Kitasato University Kitasato Institute Hospital, Centre for Advanced IBD Research and Treatment, Tokyo, Japan

OP012: Risk factors for colorectal neoplasia in ulcerative colitis: results from the largest and longest-running colonoscopic surveillance programmeECCO '16 Amsterdam
Year: 2016
Authors:

C. H. R. Choi*1, 2, I. Al Bakir1, 2, N. S. J. Ding1, M. Moorghen1, S. Thomas-Gibson1, J. Warusavitarne1, B. Saunders1, M. Rutter3, T. Graham2, A. Hart1

1St. Mark’s Hospital, London, United Kingdom, 2Barts Cancer Institute, Tumour Biology, London, United Kingdom, 3University Hospital of North Tees, Department of Gastroenterology, Stockton-on-Tees, Teesside, United Kingdom

OP013: Evolution of corticosteroid use in Crohns disease patients between 1991 and 2014: results from the Dutch population-based Inflammatory Bowel Disease South Limburg cohortECCO '16 Amsterdam
Year: 2016
Authors:

S. Jeuring*1, 2, V. Biemans1, L. Liu1, T. Van den Heuvel1, 2, M. Zeegers3, 4, 
W. Hameeteman1, M. Romberg-Camps5, L. Oostenbrug6, A. Masclee1, 2, D. Jonkers1, 2, M. Pierik1, 2

1Maastricht University Medical Centre, Internal Medicine - Division of Gastroenterology and Hepatology, Maastricht, Netherlands, 2Maastricht University Medical Centre, NUTRIM - School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, 3Maastricht University Medical Centre, Complex Genetics - School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht, Netherlands, 4Maastricht University Medical Centre, CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands, 5Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Sittard-Geleen, Netherlands, 6Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Heerlen, Netherlands

OP014: A multicentre, double-blind, placebo-controlled phase 3 study of ustekinumab, a human interleukins-12/23p40 mab, in moderate-severe Crohns disease refractory to anti-tumour necrosis factor α: UNITI-1ECCO '16 Amsterdam
Year: 2016
Authors:

P. Rutgeerts*1, C. Gasink2, M. Blank3, Y. Lang2, J. Johanns2, L.-L. Gao2, B. Sands4, S. Hanauer5, B. Feagan6, S. Targan7, S. Ghosh8, W. de Villiers9, J.-F. Colombel10, S. Lee11, P. Desreumaux12, E. V. Loftus, Jr13, S. Vermeire14, W. J. Sandborn15

1University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands, 2Janssen R & D, LLC, Spring House, United States, 3Janssen Scientific Affairs, LLC., Horsham, United States, 4Mount Sinai Medical Centre, New York, New York, United States, 5Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States, 6Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada, 7Cedars-Sinai Medical Centre, Division of Gastroenterology, Los Angeles, California, United States, 8University of Calgary, Department of Gastroenterology, Calgary, Canada, 9Universiteit Stellenbosch University, Stellenbosch, South Africa, 10Mount Sinai, Icahn School of 
Medicine, New York, New York, United States, 11University of Washington, Seattle, Washington, United States, 12University of Lille, Lille, France, 13Mayo Clinic Rochester, Department of Gastoenterology, Rochester, Minnesota, United States, 14University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, 15University of California San Diego, Division of Gastroenterology, La Jolla, California, United States